Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1
Avinash Hosanagar, Joseph Michael Cusimano, Rajiv Radhakrishnan
The Journal of Clinical Psychiatry February 23, 2021 DOI: 10.4088/jcp.20ac13786 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Citations | 9 |
| Key findings | The text reports that psilocybin alters brain functional connectivity, reducing negative affect, amygdala response to emotional faces, and default mode network activity in healthy individuals. In contrast, in treatment-resistant depression, two psilocybin treatments were associated with increased resting-state connectivity within the default mode network, which predicted clinical response five weeks posttreatment. |
Abstract
PsilocybinPsilocybin, derived from mushrooms belonging to the genus Psilocybe, and psilocin, its active metabolite, are indolamines.Recent studies have shown that psilocybin has effects on brain functional connectivity.14 Its effects include reducing negative affect and amygdala response to emotional faces at 1 week, with enduring changes in resting state functional connectivity (RSFC) at 1 month, 15 along with reducing activity in the default mode network (DMN) (including the subgenual cingulate cortex) in healthy individuals 16 and causing changes in synaptic plasticity.13 Contrary to the finding in healthy individuals, psilocybin was associated with increased resting state connectivity within the DMN between the ventromedial prefrontal cortex and the bilateral inferior-lateral parietal cortex after 2 psilocybin treatments in treatment-resistant depression patients and was predictive of clinical response 5 weeks posttreatment.17
Citations in the library
Cited by 8
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder The Canadian Journal of Psychiatry August 17, 2022
- Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. Journal of Palliative Medicine August 1, 2022
- A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond Biotechnology Advances August 31, 2023
- Role of Psychedelics in Treatment-Resistant Depression. Psychiatric Clinics of North America June 1, 2023
- Psychedelic use and psychological flexibility: The role of meaningful intention and decentering Journal of Psychedelic Studies August 16, 2024
and 3 more in the library
Cites 23
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences April 11, 2016
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- The Pharmacology of Lysergic Acid Diethylamide: A Review CNS Neuroscience & Therapeutics November 11, 2008
and 18 more in the library